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Abstract 
Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation 
has been shown to have a beneficial effect on bone turnover markers (BTM) in 
postmenopausal women. However, the effect of soy supplementation on BTM in T2DM and 
particularly in men is unclear.  We performed an analysis of a randomized double blind 
parallel study of 200 men with T2DM treated with soy, either with or without isoflavones. 
Outcome measures were type I collagen crosslinked beta C-telopeptide (βCTX), and type 1 
procollagen-N-propeptide (P1NP). The men, with a total testosterone<12nmol/L, were 
treated with 15g soy protein containing 66mg of isoflavones (SPI) or 15g soy protein alone 
without isoflavones (SP) daily for three months. There was a 15% reduction in βCTX after 
three months of SPI compared to SP supplementation. There was no significant difference in 
P1NP with either SPI or SP supplementation. There was a significant linear correlation 
between the reduction in βCTX in the SPI group with the reduction in HbA1c (r2=0.42; 
p=0.04) and HOMA-IR (r2=0.54; p=0.02). Our study indicates that there was a significant 
reduction in bone resorption following 3 months of SPI supplementation that correlated with 
an improvement of glycemic control in men with T2DM.   
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Background 
There is substantial epidemiological evidence that people with T2DM has increased risk of 
fractures 1,2. This increase in fracture risk occurs despite bone mineral density (BMD) being 
comparatively higher in those with T2DM than those without. In a meta-analysis, 
Vestergaard reported an increased Z-score of 0.41 at the spine and 0.27 at the hip associated 
with T2DM 2. T2DM has been shown to be an independent risk factor for fractures, which is 
not attributable to increased body mass index (BMI) or other classical osteoporosis risk 
factors 3.  
Testosterone is anabolic for bone primarily through its aromatization to estrogen in adipose 
tissue 4. Low testosterone in the setting of low or inappropriately normal luteinizing hormone 
and follicle-stimulating hormone is common in the diabetes population and may contribute to 
impaired bone strength in these men with T2DM 5. 
Production and consumption of soy foods within Western countries have increased 
dramatically with postulated health benefits including improvement in bone health, especially 
in women 6. Habitual intake of soy isoflavones has also been associated with a reduced risk 
of T2DM and cardiovascular disease (CVD) 7. 
Bone turnover markers (BTMs) are biomarkers for fracture risk that have been used for the 
evaluation of effects of osteoporosis treatments, and include both bone resorption markers 
(e.g. type I collagen crosslinked Beta C-telopeptide (βCTX)) and bone formation markers 
(e.g. type I procollagen-N-propeptide (PINP)). Hypogonadal men with type 2 diabetes have 
smaller bone size and lower bone turn over8. We conducted this analysis to study the effect of 
soy isoflavone supplementation on BTMs in men with T2DM and low testosterone levels 
(<12 nmol/L).   
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Research Design and Methods 
This post-hoc analysis included data from men who had participated in a randomized double 
blind parallel study investigating the effect of soy isoflavones on testosterone concentrations 
in men with T2DM9. 412 Caucasian male patients with T2DM were screened. 200 men 
between 45 to 75 years of age with an early morning total testosterone concentrations of less 
than 12 nmol/L (normal range – 12 - 25 nmol/L) on at least 2 different occasions with a 
normal FSH and LH, and a HbA1c of less than 9 % (<75mmol/mol) were recruited. Subjects  
were randomised either to 15g soy protein alone (SP) (all isoflavones removed by serial 
alcohol washing9) per day or 15g soy protein with 66mg of isoflavones (SPI) per day for 3 
months.  
Subjects were on stable medications for hypertension, hyperlipidemia and T2DM for at least 
3 months prior to the study. Those with significant renal or hepatic impairment, receiving 
testosterone replacement, who were allergic to soy products, or who had received antibiotics 
3 months prior to the study were excluded. Participants were instructed to maintain their level 
of physical activity throughout the study. Participants were required to avoid food products 
containing alcohol, soy, alcohol, mineral or vitamin supplementation, and any over-the-
counter medications. Plasma isoflavone concentrations were measured at each visit to ensure 
adherence. All methods were performed in accordance with the relevant guidelines and 
regulations. All subjects gave their written informed consent. Ethical approval was given by 
East Yorkshire & North Lincolnshire Research Ethics Committee, ref: 09/H1304/45.    
 
Study product 
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Bar containing 7.5g of the isoflavone-free soy protein (SP) or 7.5g isolated soy protein 
powder (Solcon F, Solbar Industries, Ashdod, Israel) with 33mg of isoflavones (Solgen 40, 
Solbar Industries Israel) (SPI) was consumed twice daily for 3 months. Essential Nutrition 
Ltd, Brough, UK performed randomization based on a computer generated randomization 
list.  
Bone turn over markers 
Plasma P1NP and βCTX were measured using an electrochemiluminescent immunoassay 
(Roche Diagnostics, Lewes, UK). Inter/Intra assay coefficient of variation of plasma βCTX 
were both <4% between 0.2 and 1.5µg/L. The assay sensitivity was 0.01 µg/L. Inter/ Intra 
assay CV of plasma P1NP were both <3% between 20-600 µg/L. The assay sensitivity was 8 
µg/L. 
LC-MS/MS was used to extract and analyse serum phytoestrogens10. The inter assay CVs 
were less than 7.4% for equol, less than 6.1% for genistein and less than 6.8% for daidzein 
between 0.5 ng/mL to 200 ng/mL. The intra assay CVs were less than 8.0% for equol, less 
than 3.6% for genistein and less than 7.2% for daidzein between 0.5 ng/mL to 200 ng/mL. 
Statistical analysis 
The sample size was initially calculated based on the aims of the primary study9. Based on a 
study using the same soy preparation on bone turnover markers involving post-menopausal 
women11, a post hoc power analysis for changes in βCTX and P1NP using N-query software, 
for 90% power, 2-tailed with an alpha of 0.05 required 12 subjects per arm for βCTX  and 60 
subjects per group for P1NP, including a 20% dropout rate.  
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Baseline continuously distributed data is presented as median (25th/75th centiles); categorical 
data by n (%). Within-group differences (difference between 12 week values and baseline 
values) are shown for each treatment group separately by a mean and a standard deviation 
(SD). Between-group comparisons were performed using the independent sample t-test. A 
two-tailed P <0.05 was considered to indicate statistical significance for all analysis. 
Bonferroni corrections were not applied 12. STATA statistical computer package (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP, USA) was 
used for statistical analysis.  
Results 
412 participants were screened and 200 with T2DM and low testosterone concentrations were 
recruited. 29 patients dropped out (14 patients SP group and 15 patients SPI group)9 . The 
baseline parameters of the two groups are given in Table 1.   
There was a 15% decrease in βCTX with 3 months of SPI supplementation.  There were no 
changes in P1NP with either SPI or SP supplementation (Table 2). The changes in βCTX 
with SPI supplementation were significantly greater when compared to three months of SP 
supplementation.   
There was a significant linear correlation between reduction in βCTX in the SPI group with 
reduction in HOMA-IR (r2=0.54; p=0.02) and HbA1c (r2=0.42; p=0.04). There were no 
correlations between a reduction in βCTX with changes in triglycerides (r2=0.10; p=0.48), 
hsCRP (r2=0.26; p=0.33), fT4 (r2=0.10; p=0.69) or TSH (r2=0.12; p=0.72) concentrations in 
the SPI group.   There was also no correlation between changes in βCTX with SPI 
supplementation with changes in daidzein (r2=0.16; p=0.22), genistein (r2=0.13; p=0.54) and 
equol (r2=0.20; p=0.77) concentrations.   
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Discussion 
In this study, there was a significant reduction in the bone resorption marker βCTX after 
three months of combined soy protein and isoflavone supplementation in men with T2DM.  
The reduction in βCTX was correlated with an improvement in glycemic control and insulin 
resistance suggesting the effect of soy in bone may be mainly through modifying insulin 
resistance. 
Patients with T2DM have increased risk of fractures especially of hip 1,2. In the Rotterdam 
Study, an increased fracture risk for nonvertebral fractures (hip and wrist) was described [HR 
1.33 (1.00-1.77)] despite higher BMD 13. In subset analysis, the increased fracture risk 
seemed to be restricted to treated T2DM [HR 1.69 (1.16-2.46)], with subjects with impaired 
glucose tolerance showing a reduced fracture risk. This decreased bone strength may develop 
as a consequence of insulin resistance associated with T2DM and of particular relevance with 
the finding here of the decrease in βCTX associated with a decrease in insulin resistance. An 
inverse association of fasting insulin with periosteal circumference has been reported in 
healthy adolescents 14,15, and insulin resistance correlated inversely with periosteal and 
endosteal circumference 16, 17. Other putative indirect mechanisms whereby insulin resistance 
may affect bone involve a suggested role of hyperinsulinemia in bone ageing 18,19, reduced 
blood flow to the bone tissue adversely affecting bone remodeling 19 and it has been shown 
that osteoblast-specific disruption of the insulin receptor leads to impaired osteoblast 
differentiation and reduced trabecular bone formation 20,21. Experimental studies indicated 
that similar to skeletal muscle, hepatic, and adipose tissue, insulin resistance can develop in 
bone tissue, and that this compromised insulin signaling is associated with decreased bone 
remodeling22. Hence improving insulin resistance through soy preparations with a 
combination of soy protein and isoflavone could potentially improve bone health as shown in 
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this study.  
The isoflavone concentrations used in the study preparation reflects the daily intake of Asian 
population consuming high soy diet or people consuming soy supplements of around 50-
90mg per day23,24. Epidemiological studies generally suggest a positive association between 
soy consumption and BMD 25. Isoflavones are heterocyclic phenols found in various plant 
products including soy, the main constituents of which are genistein, daidzein and glycitein.  
They have a similar structure to 17 beta estradiol and have been shown to have biological 
activity exerting estrogen-like effects both in vitro and in vivo. Estrogen can increase BMD 
and has a protective effect on bones in females. In the present study, there was a mean 15% 
reduction in βCTX suggesting beneficial effects on bones.  These findings are similar to our 
previous observation in post-menopausal women using similar soy preparations 11 in which 
there was a significant reduction in βCTX after 6 months of SPI preparation compared to SP 
preparation 11. Potent anti-resorptive agents such as bisphosphonates and denosumab, act by 
reducing bone turn over although to a greater magnitude 26. Treatment with bisphosphonate 
reduce CTX by around 40 - 50% 27,28. The reduction of CTX by isoflavones compares well 
with dietary treatments11 and could possibly be used in combination with other anti-
osteoporotic drug treatments. 
In patients with T2DM circulating biochemical markers of bone formation are decreased 29-31. 
In post-menopausal women using a similar soy preparation, changes in P1NP were more 
pronounced, with a significant decrease in P1NP after 6 months of SPI preparation 11.  In the 
current study, there were no significant changes in P1NP after 3 months of SPI 
supplementation that may be due to shorter duration of supplementation.  
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There were no correlation of changes in βCTX with changes in plasma isoflavones including 
daidzein, genistein and equol suggesting that the effect of SPI on this bone turnover marker is 
not a direct effect.  This lack of association could also be due to the fact that since the same 
dose was given to participants, their plasma isoflavones were raised to the same degree but 
the difference in response to the isoflavones could be due to unmeasured factors such as 
difference in genetic background and metabolism. There was no correlation of changes in 
βCTX with changes in lipids or hsCRP, which is an inflammatory marker. 
The strengths of this study include that a comparison with a confirmed isoflavone free 
preparation was undertaken and isoflavone measurement confirmed compliance. Although 
the study was not powered primarily to look at changes in bone turn over markers, based on 
another report of bone turnover markers 11 this study had significant power to detect changes 
in those markers, accounting for drop outs. 
In conclusion, combined soy protein and isoflavone supplementation for three months in men 
with T2DM significantly reduced the bone-resorption marker βCTX that correlated with an 
improvement in glycemic control and insulin resistance, suggesting that the effect of soy 
protein with isoflavones in bone may be mediated through modifying insulin resistance. 
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Table 1. Baseline parameters between the SPI and SP groups.  
 
Parameters SP1 group (n=100) SP group (n=100) 
Age (years) 52.0 (50.0, 55.0) 52.0 (50.0, 55.0) 
Weight  100.1(88.5,112.3) 98(85.7,111.9) 
Body Mass Index (kg/m2) 31.8(28.8,34.7) 
 
31.6(29.2,35.0) 
Duration of diabetes (years) 7.3 (4.2,8.8) 7.9 (4.4, 9.1) 
HbA1c (mmol/mol) 56 (52,60) 58(53,64) 
TSH (mU/L) 1.6 (1.2, 2.4) 1.6 (1.2, 2.5) 
fT4 (pmol/L) 12.0 (12.0, 14.0) 13.0 (12.0, 14.0) 
Fasting glucose (mmol/L) 139.5 (118.8, 160.7) 135.9 (115.2, 154.4) 
Fasting insulin (µIU/mL) 16.5 (9.9, 25.3) 18.0 (10.4, 28.6) 
HOMA-IR 5.6 (3.6, 9.0) 6.2 (3.8, 9.7) 
hsCRP (mg/L) 2.1 (0.8, 3.9) 1.9 (0.9, 4.1) 
TC (mmol/L) 3.9 (3.4, 4.6) 3.8 (3.4, 4.5) 
LDL-C (mmol/L) 2.0 (1.7, 2.9) 2.0 (1.6, 2.7) 
HDL-C (mmol/L) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 
Triglycerides (mmol/L) 1.4 (1.0, 2.1) 1.3 (0.9, 2.0) 
Daidzein (ng/mL) 1.4 (0.6, 2.7) 1.9 (0.7, 4.3) 
Genistein (ng/mL) 2.6 (0.7, 5.7) 2.9 (1.3, 7.2) 
Equol (ng/mL) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 
 
SPI (15 g soy protein with 66 mg of isoflavones); SP (15 g soy protein alone without any 
isoflavones) 
Values are provided as medians (25th/75th centiles). 
To convert values for glucose to milligrams per deciliter, divide by 0.056.  
To convert values for insulin to picomoles per liter, multiply by 6.  
To convert values for cholesterol to milligrams per deciliter divide by 0.0259. 
To convert values for triglycerides to milligrams per deciliter divide by 0.0113.  
TC - Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL cholesterol; TG-
Triglycerides; HbA1c – glycated hemoglobin; HOMA – Homeostasis model of assessment – 
insulin resistance; HsCRP – highly sensitive C-respire protein; FSH – follicle stimulating 
hormone; LH – Luteinizing hormone; SHBG – sex hormone binding globulin; TSH – thyroid 
stimulating hormone; fT4 – free thyroxine; fT3 – free tri-iodo thyronine 
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Table 2. Comparison between SPI and SP supplementation at end of study of bone 
turnover markers.   
Parameters 
SPI SP 
Difference 
of the 
difference 
p-value 
Baseline 
Mean 
(SD) 
3 
months 
Mean 
(SD) 
p value 
(3 mo – 
baseline) 
Baseline 
Mean 
(SD) 
3 
months 
Mean 
(SD) 
p value 
(3 mo – 
baseline) 
Bone turn over markers 
βCTX 
(µg/L) 
0.22 
(0.09) 
0.19 
(0.08) 
     0.04 
0.22 
(0.10) 
0.22  
(0.11) 
0.89 <0.01 
P1NP 
(µg/L) 
31 (12) 32 (11) 0.66 33 (13) 33(12)      0.352 0.322 
 
Paired difference=3-months-baseline.  Difference of the difference is an unpaired t-test of the 
paired differences. 
SPI (15g soy protein with 66mg of isoflavones); SP (15g soy protein alone isoflavone free) 
BTM – bone turnover marker 
βCTX  - collagen type 1 cross-linked Beta C-telopeptide  
P1NP - propeptide of type I collagen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
